Fennec製藥 FENC 深 滬

Earnings Scheduled For March 24, 2026

Companies Reporting Before The Bell • Fennec Pharmaceuticals (NASDAQ:FENC) is e...

03-24 19:11

Fennec Pharmaceuticals Q4 EPS $(0.17) Misses $0.04 Estimate, Sales $13.777M Miss $13.993M Estimate

Fennec Pharmaceuticals (TSX:FRX) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $0.04 by 572.22 percent. This is a 183.33 percent decrease over losses of $(0.06) per share

03-24 19:04

Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Fennec Pharmaceuticals (FENC) to release Q4 earnings on March 24. Analysts expect EPS of $0.04 and revenue of $14.73 million. Stock gained 1.8% on Monday.

03-24 04:40

Fennec Pharmaceuticals Settles PEDMARK Patent Litigation With Cipla; Blocking Generic Entry Until September 2033

Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the litigation between them

03-16 20:13

Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation

03-16 12:08

Fennec Pharma Backs Real-World Study Of PEDMARK To Protect Hearing In Cancer Patients

Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced that the Tampa General Hospital (TGH) Cancer Institute is initiating a study evaluating the real-world clinical

03-04 20:09

Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute

Fennec Pharmaceuticals Inc. announced that Tampa General Hospital (TGH) Cancer Institute is initiating a study to evaluate the real-world clinical utility of sodium thiosulfate injection (PEDMARK®) in reducing the risk of ototoxicity in Adolescent and Young Adult (AYA) and adult cancer patients receiving cisplatin-based treatment. PEDMARK® is currently approved for pediatric patients one month of age and older with localized non-metastatic solid ...

03-04 12:05

Fennec Pharmaceuticals reports real-world data supporting PEDMARK use after cisplatin in adult head and neck cancer patients

Fennec Pharmaceuticals reports real-world data supporting PEDMARK use after cisplatin in adult head and neck cancer patients Fennec Pharmaceuticals Inc. announced new real-world data on PEDMARK (sodium thiosulfate injection) use in adults with head and neck cancers from a multi-institutional retrosp

02-20 20:03

Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers

Study highlights that PEDMARK® (sodium thiosulfate injection) can be safely administered ≥6 hours after cisplatin in adults with head and neck cancers (HNC), without compromising cisplatin's antitumor activity. Most high-risk patients experienced no measurable hearing loss during or after treatment, suggesting PEDMARK®'s potential to address cisplatin-induced hearing loss, a significant survivorship issue. The study supports broader clinical adop...

02-20 12:03

U.S. RESEARCH ROUNDUP-Equinix, Generac Holdings, Gilead

U.S. RESEARCH ROUNDUP-Equinix, Generac Holdings, Gilead Feb 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Equinix, Generac Holdings and Gilead, on Thursday. HIGHLIGHTS * Equinix Inc EQIX.O : Jefferies raises target

02-12 15:22